Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A phase 3 randomized trial

By sjmartinez • November 14, 2024

Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Ansari W, Harrington MA, Simón-Campos A, Chew KW, Pypstra R, Rusnak JM. Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A phase 3 randomized trial. Clin Infect Dis. 2024 Nov 11:ciae551. doi: 10.1093/cid/ciae551. Epub ahead of print. PMID: 39523543.

Tags: COVID-19 drug therapy, EPIC-HR, Infectious Diseases, nirmatrelvir, Publications, ritonavir, Symptoms

Related Posts

Barriers to viral suppression in children aged 9 years or younger on dolutegravir-based antiretroviral therapy in Malawi, a mixed-methods study

Phiri K, Hagstrom C, Lungu E, Balakasi K, Songo J, Makwaya A, Smith D, Worku A, Hoffman R, Phiri S, Dovel K, van Oosterhout JJ.[...]

Single-cell analyses identify monocyte gene expression profiles that influence HIV-1 reservoir size in acutely treated cohorts

Ehrenberg PK, Geretz A, Volcic M, Izumi T, Yum LK, Waickman A, Shangguan S, Paquin-Proulx D, Creegan M, Bose M, Machmach K, McGraw A, Narahari[...]

HIV-Superinfection in Kidney Transplant Recipients with HIV who Received Organs from Donors with HIV

Rozek GM, Yang P, Eby Y, Benner SE, Martens C, Habtehyimer F, Chahoud M, Brown D, Desai NM, Florman S, Rana MM, Pereira MR, Hand[...]